13) A cell according to claim 12, wherein the knockout mutated ptr gene and/or the knockout mutated Tsp gene are mutated to comprise a restriction marker site comprising an in-frame stop codon.

14) A cell according to claim 12 , wherein the restriction marker site is an Ase I restriction site.

15) A cell according to any one of claims 12 to 14, wherein the knockout mutated ptr gene and/or the knockout mutated Tsp gene comprise a restriction marker site created by a missense mutation to the gene start codon and optionally one or more further point mutations.

16) A cell according to claim 15, wherein the restriction marker site is an EcoR I marker site.

17) A cell according to claim 5, wherein the knockout mutated Tsp gene comprises SEQ ID NO:3.

18) A cell according to claim 6 , wherein the knockout mutated ptr gene comprises SEQ ID NO:6.

19) A cell according to any one of the preceding claims wherein the mutated DegP gene comprises the mutation S210A.

20) A cell according to claim 19, wherein the mutated DegP gene comprises SEQ ID NO:9.

21) A cell according to any one of the preceding claims, wherein the cell is *E. coli*.

22) A cell according to any one of the preceding claims, wherein the cell further comprises a polynucleotide sequence encoding a protein of interest.

23) A cell according to claim 22, wherein the cell comprises an expression cassette or a vector comprising the polynucleotide sequence encoding the protein of interest.

24) A cell according to claims 22 or 23, wherein the protein of interest is an antibody or an antigen binding fragment thereof.

25) A cell according to claim 24, wherein the antibody or antigen binding fragment thereof is specific for TNF.

26) A method for producing a recombinant protein of interest comprising expressing the recombinant protein of interest in a recombinant gram-negative bacterial cell as defined in any one of claims 1 to ~~26~~25.